Home LiteratureArticle Details
PMID: 18405521 Published · ppublish spa English Abstract Journal Article Review

[Risk functions and the primary prevention of cardiovascular disease].

Funciones de riesgo en la prevención primaria de las enfermedades cardiovasculares.

Revista espanola de cardiologia ·Vol. 61 ·No. 4 ·2008-04-00 ·Pages 404-16

Grau M, Marrugat J

Abstract

Cardiovascular risk functions are regarded as the best tools for establishing priorities in primary prevention. Since the original Framingham risk chart fell into disuse because it greatly overestimated the real risk, the adjusted REGICOR and SCORE functions have become widely available in Spain, although the REGICOR function is the only one that has been validated for use in the Spanish population. Risk estimates have been shown to be useful for decision-making, particularly on the treatment of hypercholesterolemia. However, the fact that the majority of cardiovascular events occurs in individuals classified as being at a medium risk is evidence for the poor discriminative ability of classical risk factors. Despite the use of new parameters proposed for estimating cardiovascular risk, such as the C-reactive protein level, the detection of coronary calcification, the carotid intima-media thickness and the ankle-brachial index, there has been no improvement in the predictive capacity of classical risk factors. The most promising alternative seems to be the identification of "vulnerable patients" using markers of vulnerable plaque (ie, unstable or high-risk plaque), vulnerable blood (ie, with a tendency for thrombosis), and vulnerable myocardium (ie, electrically unstable or with a tendency for arrhythmia). In this article, we discuss whether the combined use of cardiovascular risk functions, novel risk markers and noninvasive tests can be effective in increasing the accuracy of patient selection for the primary prevention of cardiovascular disease.

MeSH Terms
Cardiovascular Diseases/diagnosis,epidemiology,etiology,prevention & control Dyslipidemias/complications,drug therapy Humans Hypolipidemic Agents/therapeutic use Risk Assessment
Chemicals
Hypolipidemic Agents
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Grau María
Unitat de Lipids i Epidemiologia Cardiovascular, Institut Municipal d'Investigació Mèdica, Barcelona, España.
Marrugat Jaume
Article Info
Journal
Revista espanola de cardiologia
Abbr.
Rev Esp Cardiol
ISSN
1579-2242
Published
2008-04-00
Pages
404-16
Language
spa
Region
Spain
NLM ID
0404277
Subset
IM
Corrections
CommentIn
External Links
PubMed source
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]